Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis (Q43601186)

25 November 2017

title

Genotypic resistance profiles associated with virological failure to darunavir-containing regimens: a cross-sectional analysis (English)

1 reference

25 November 2017

0 references

F Baldanti

4

0 references

Maurizio Zazzi

object named as

M Zazzi

8

0 references

author name string

G Sterrantino

1

1 reference

25 November 2017

M Zaccarelli

2

1 reference

25 November 2017

G Colao

3

1 reference

25 November 2017

S Di Giambenedetto

5

1 reference

25 November 2017

T Carli

6

1 reference

25 November 2017

F Maggiolo

7

1 reference

25 November 2017

ARCA Database Study Group

9

1 reference

25 November 2017

publication date

12 January 2012

1 reference

25 November 2017

1 reference

25 November 2017

volume

40

1 reference

25 November 2017

issue

3

1 reference

25 November 2017

page(s)

311-318

1 reference

TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Discovery and selection of TMC114, a next generation HIV-1 protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Mutations associated with virological response to darunavir/ritonavir in HIV-1-infected protease inhibitor-experienced patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Darunavir inhibitory quotient predicts the 48-week virological response to darunavir-based salvage therapy in human immunodeficiency virus-infected protease inhibitor-experienced patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

ARTEMIS: 192-week efficacy and safety of once-daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment-naïve HIV-1-infected adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Resistance profile of darunavir: combined 24-week results from the POWER trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Predicting tipranavir and darunavir resistance using genotypic, phenotypic, and virtual phenotypic resistance patterns: an independent cohort analysis of clinical isolates highly resistant to all other protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS15010-011-0237-Y

Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

21 January 2018

1 reference

12 December 2020

Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3.

1 reference

12 December 2020

Clinically validated genotype analysis: guiding principles and statistical concerns.

1 reference

12 December 2020

Virological response to darunavir/ritonavir-based regimens in antiretroviral-experienced patients (PREDIZISTA study).

1 reference

12 December 2020

Combating susceptibility to drug resistance: lessons from HIV-1 protease.

1 reference

12 December 2020

Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients

1 reference

12 December 2020

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors

1 reference

12 December 2020

Update of the drug resistance mutations in HIV-1: December 2010.

1 reference

12 December 2020

10.1007/S15010-011-0237-Y

Identifiers

DOI

1 reference

25 November 2017

1 reference